5-Chloro-2-ethyl-3-phenyl-3H-quinazolin-4-one | 27331-60-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-Chloro-2-ethyl-3-phenyl-3H-quinazolin-4-one
• 英文别名: 5-Chloro-2-ethyl-3-phenylquinazolin-4-one
• CAS: 27331-60-8
• 化学式: C₁₆H₁₃ClN₂O
• 分子量: 284.745
• InChiKey: CWIMJKVIYPTZMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE OU DE PYRIDINE UTILES EN TANT QU'INHIBITEURS DE PI3K
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2015168079A1

  公开（公告）日：2015-11-05

  Compounds (I) and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

  本文描述了调节激酶活性，包括PI3激酶活性的化合物(I)和药物组合物，以及与激酶活性，包括PI3激酶活性相关的疾病和病状的治疗方法、化合物和药物组合物。
• [EN] SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS SUBSTITUÉS D'AMINOPYRIMIDINE ET PROCÉDÉS D'UTILISATION
  申请人：CALITOR SCIENCES LLC

  公开号：WO2015042077A1

  公开（公告）日：2015-03-26

  The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukernias and solid tumors, in mammals, especially humans.

  本发明涉及新的氨基嘧啶衍生物的制备和应用，作为自由形式或药物可接受的盐形式和制剂的药物候选物，用于调节由PI3K酶活性介导的疾病或疾病。本发明还提供了包含这种化合物的药物可接受的组合物和使用这些组合物治疗疾病或疾病的方法，例如，PI3K酶在白细胞功能中发挥作用的免疫和炎症疾病，以及与PI3K活性相关的高增殖性疾病，包括但不限于哺乳动物，特别是人类的白血病和实体肿瘤。
• HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Korea Research Institute of Chemical Technology

  公开号：EP3312175A1

  公开（公告）日：2018-04-25

  The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting PI3 kinases, thereby being useful in preventing or treating PI3 kinase diseases such as: cancers such as hematologic malignancy, ovarian cancer, uterine cervical cancer, breast cancer, colorectal cancer, liver cancer, gastric cancer, pancreatic cancer, colon cancer, peritoneal metastatic cancer, skin cancer, bladder cancer, prostate cancer, lung cancer, osteosarcoma, fibrous tumors, and brain tumors; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosis, multiple sclerosis, diabetes mellitus, hyperthyroidism, myasthenia, Crohn's disease, ankylosing spondylitis, autoimmune pernicious anemia, and Sjogren's syndrome; and respiratory diseases such as chronic obstructive pulmonary disease (COPD), rhinitis, asthma, chronic bronchitis, chronic pulmonary inflammatory diseases, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, angitis, pneumatosis, pneumonia, and bronchiectasis.

  本发明涉及一种杂芳基衍生物或其药学上可接受的盐、其制备方法以及一种用于预防或治疗与PI3激酶相关疾病的药物组合物，其中含有杂芳基衍生物或其药学上可接受的盐、其制备方法以及一种用于预防或治疗与PI3激酶相关疾病的药物组合物，其中含有杂芳基衍生物或其药学上可接受的盐作为活性成分。根据本发明的杂芳基衍生物具有很好的选择性抑制 PI3 激酶的效果，因此可用于预防或治疗 PI3 激酶疾病，如癌症，如血液系统恶性肿瘤、卵巢癌、子宫颈癌、乳腺癌、结直肠癌、肝癌、胃癌、胰腺癌、结肠癌、腹膜转移癌、皮肤癌、膀胱癌、前列腺癌、肺癌、骨肉瘤、纤维瘤和脑瘤；自身免疫性疾病，如类风湿性关节炎、系统性红斑狼疮、多发性硬化症、糖尿病、甲状腺机能亢进症、肌无力、克罗恩病、强直性脊柱炎、自身免疫性恶性贫血和 Sjogren 综合征；呼吸系统疾病，如慢性阻塞性肺病（COPD）、鼻炎、哮喘、慢性支气管炎、慢性肺部炎症、矽肺、肺肉瘤病、胸膜炎、肺泡炎、血管炎、肺气肿、肺炎和支气管扩张。
• CASEIN KINASE 1epsilon INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
  申请人：Hangzhou Healzen Therapeutics Co., Ltd.

  公开号：EP3964512A1

  公开（公告）日：2022-03-09

  Disclosed in the present invention is a novel substituted pyrazolopyrimidine compound that inhibits the activity of casein kinase 1ε (CK1ε) and a stereoisomer or stereoisomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, and an application thereof in preparation of drugs for treating diseases, disorders or conditions that benefit from the inhibition of the activity of the casein kinase 1ε (CK1ε). The compound of the present invention has an inhibitory activity on CK1ε kinase, OCI-LY10 cells and Karpas299 cells, shows good anti-tumor activity in an OCI-LY10 subcutaneous xenogeneic model and shows excellent synergistic anti-tumor activity in combination with BTK inhibitors. The compound of the present invention has good pharmacokinetics properties and may be used alone or in combination with other drugs to treat diseases, disorders or conditions that benefit from the inhibition of the activity of the casein kinase 1ε, the diseases, disorders or conditions comprising tumors, autoimmune diseases, etc.

  本发明公开了一种抑制酪蛋白激酶1ε（CK1ε）活性的新型取代吡唑嘧啶化合物及其立体异构体或立体异构体混合物，或其药学上可接受的盐或溶液，以及其在制备用于治疗从抑制酪蛋白激酶1ε（CK1ε）活性中获益的疾病、失调或病症的药物中的应用。本发明化合物对 CK1ε 激酶、OCI-LY10 细胞和 Karpas299 细胞具有抑制活性，在 OCI-LY10 皮下异种模型中显示出良好的抗肿瘤活性，与 BTK 抑制剂联合使用显示出优异的协同抗肿瘤活性。本发明的化合物具有良好的药代动力学特性，可单独使用或与其他药物联合使用，治疗因抑制酪蛋白激酶 1ε 的活性而获益的疾病、失调或病症，这些疾病、失调或病症包括肿瘤、自身免疫性疾病等。
• [EN] CASEIN KINASE 1ε INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF<br/>[FR] INHIBITEUR DE CASÉINE KINASE 1ε, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉE<br/>[ZH] 一种酪蛋白激酶1ε抑制剂、药物组合物及其应用
  申请人：HANGZHOU HERTZ PHARMACEUTICAL CO LTD

  公开号：WO2020259463A1

  公开（公告）日：2020-12-30

  一种抑制酪蛋白激酶1ε(CK1ε)活性的取代的吡唑并嘧啶类化合物及其立体异构体或立体异构体混合物或其药学上可接受的盐或溶剂合物及其在制备治疗从酪蛋白激酶1ε(CK1ε)活性的抑制中获益的疾病、障碍或病症药物中的应用。该化合物对CK1ε激酶和OCI-LY10细胞、Karpas299细胞具有抑制活性，并在OCI-LY10皮下异种模型中，表现出良好的抗肿瘤活性，与BTK抑制剂联用显示出优异的协同抗肿瘤活性，该化合物具有较好的药代动力学性质，可应用于在单独或与其他药物联合应用治疗从酪蛋白激酶1ε活性的抑制中获益的疾病、障碍或病症，包括癌症、自身免疫性疾病等。